Glow-in-the-Dark Infectious Disease Diagnostics Using CRISPR-Cas9-Based Split Luciferase Complementation

Harmen J. van der Veer(Eindhoven University of Technology), Eva A. van Aalen(Eindhoven University of Technology), Claire M. S. Michielsen(Eindhoven University of Technology), Eva T. L. Hanckmann(Eindhoven University of Technology), Jeroen Deckers(Eindhoven University of Technology), Marcel M. G. J. van Borren(Rijnstate Hospital), Jacky Flipse(Rijnstate Hospital), Anne J. M. Loonen(Fontys University of Applied Sciences), Joost P. H. Schoeber(Fontys University of Applied Sciences), Maarten Merkx(Eindhoven University of Technology)
ACS Central Science
March 15, 2023
Cited by 51Open Access
Full Text

Abstract

Nucleic acid detection methods based on CRISPR and isothermal amplification techniques show great potential for point-of-care diagnostic applications. However, most current methods rely on fluorescent or lateral flow assay readout, requiring external excitation or postamplification reaction transfer. Here, we developed a bioluminescent nucleic acid sensor (LUNAS) platform in which target dsDNA is sequence-specifically detected by a pair of dCas9-based probes mediating split NanoLuc luciferase complementation. LUNAS is easily integrated with recombinase polymerase amplification (RPA), providing attomolar sensitivity in a rapid one-pot assay. A calibrator luciferase is included for a robust ratiometric readout, enabling real-time monitoring of the RPA reaction using a simple digital camera. We designed an RT-RPA-LUNAS assay that allows SARS-CoV-2 RNA detection without the need for cumbersome RNA isolation and demonstrated its diagnostic performance for COVID-19 patient nasopharyngeal swab samples. Detection of SARS-CoV-2 from samples with viral RNA loads of ∼200 cp/μL was achieved within ∼20 min, showing that RPA-LUNAS is attractive for point-of-care infectious disease testing.


Related Papers

No related papers found

Powered by citation graph analysis